Next, we examined the efficacy of vepafestinib in blocking growth of 12 tumor cell lines (patient -derived and isogenic) that are models of RET fusions or RET mutations found in NSCLC and thyroid cancers and three nontumor cell lines. Here, RET is linked to neoplasm.